SLC5A2 and diabetes mellitus: The aim of this nationwide observational study based on The Swedish National Diabetes Register (NDR) was to examine outcomes and safety of treatment with GLP-1 receptor agonists compared with SGLT-2 inhibitors, in people with type 2 diabetes.